//fpnotebook.com/
Janus Kinase Inhibitor
Aka: Janus Kinase Inhibitor, Janus Kinase, JAK Inhibitor, Ruxolitinib, Jakafi, Tofacitinib, Xeljanz, Baricitinib, Olumiant, Upadacitinib, Rinvoq
- See Also
- Biologic Agent
- Indications
- Rheumatoid Arthritis
- Polycythemia Vera
- Mechanism
- Interferes with Cytokine signalling on receptor binding
- Preparations
- Ruxolitinib or Jakafi (JAK1 and JAK2 Inhibitor)
- Indicated in Rheumatoid Arthritis and Myelofibrosis (including Polycythemia Vera)
- Baricitinib or Olumiant (JAK1 and JAK2 inhibitor)
- Indicated in Rheumatoid Arthritis
- Upadacitinib or Rinvoq (JAK1 inhibitor)
- Indicated in Rheumatoid Arthritis
- Tofacitinib or Xeljanz (JAK3 Inhibitor)
- Indicated in Rheumatoid Arthritis and Psoriasis
- Multiple black box warnings
- Serious infections
- Thrombosis (e.g. Venous Thromboembolism)
- Cardiovascular events (e.g. Myocardial Infarction)
- Lung Cancer
- Increased mortality
- References
- (2021) Presc Lett 28(4): 22
- Adverse Effects
- Venous Thromboembolism
- Sudden cardiovascular death (associated with Tofacitinib)
- Immunosuppression
- Tuberculosis reactivation risk
- Increased risk of Pneumonia, Shingles
- Precautions
- Avoid Live Vaccines
- References
- (2019) Presc Lett 26(10): 58